Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $29.94 million.

GUIDANCE:

Halozyme Therapeutics sees FY2016 revenue of $140-150 million, versus prior guidance of $130-145 million and the consensus of $136.7 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold